PP
AGRX

Paloma Partners’s Agile Therapeutics AGRX Stock Holding History

Paloma Partners’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8
Closed -$42K – 2600
2020
Q2 		$42K Buy
+8
New +$41.6K ﹤0.01% 2004
2017
Q3 		– Sell
-25
Closed -$185K – 2541
2017
Q2 		$185K Buy
+25
New +$173K ﹤0.01% 2016

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paloma Partners's AGRX Position: Q3 2020 in Review

Paloma Partners sold out of Agile Therapeutics (AGRX) in Q3 2020, closing a stake of 8 shares — an estimated $42K sold.

Paloma Partners first reported a position in AGRX in Q2 2017 and held it in 2 quarters. The position peaked at $185K in Q2 2017. 75 funds tracked by Wall St. Rank hold AGRX as of Q3 2020.

  • Paloma Partners reported no remaining Agile Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 8 Agile Therapeutics shares in Q3 2020, an estimated $42K.
  • Paloma Partners first reported a position in Agile Therapeutics in Q2 2017 and held it in 2 quarters.
  • Paloma Partners's Agile Therapeutics position peaked at $185K in Q2 2017.
  • 75 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.